File(s) under permanent embargo
Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity
journal contributionposted on 2023-05-17, 22:32 authored by Johnson Liu, Jamiesom, SMF, Subramaniam, J, Ip, V, Jong, NN, Mercer, JFB, McKeage, MJ
Abstract Purpose We report the neuronal expression of copper transporter 1 (CTR1) in rat dorsal root ganglia (DRG) and its association with the neurotoxicity of platinum-based drugs. Methods CTR1 expression was studied by immunohistochemistry and RT-PCR. The toxicity of platinum drugs to CTR1-positive and CTR1-negative neurons was compared in DRG from animals treated with maximum tolerated doses of oxaliplatin (1.85 mg/kg), cisplatin (1 mg/kg) or carboplatin (8 mg/kg) twice weekly for 8 weeks. Results Abundant CTR1 mRNA was detected in DRG tissue. CTR1 immunoreactivity was associated with plasma membranes and cytoplasmic vesicular structures of a subpopulation (13.6 ± 3.1%) of mainly large-sized (mean cell body area, 1,787 ± 127 lm2) DRG neurons. After treatment with platinum drugs, the cell bodies of these CTR1-positive neurons became atrophied, with oxaliplatin causing the greatest percentage reduction in the mean cell body area relative to controls (42%; P\0.05), followed by cisplatin (18%; P\0.05) and carboplatin causing the least reduction (3.2%; P = NS). CTR1-negative neurons, with no immunoreactivity or only diffuse cytoplasmic staining, showed less treatment-induced cell body atrophy than CTR1-positive neurons. Conclusions CTR1 is preferentially expressed by a subset of DRG neurons that are particularly vulnerable to the toxicity of platinum drugs. These findings, together with its neuronal membrane localization, are suggestive of CTR1- related mechanisms of platinum drug neuronal uptake and neurotoxicity.
Publication titleCancer Chemotherapy and Pharmacology
Department/SchoolSchool of Pharmacy and Pharmacology
Place of publication175 Fifth Ave, New York, USA, Ny, 10010
Rights statementCopyright 2009 Springer-Verlag